Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.
Tycel Jovelle Phillips, MD, University of Michigan
Advertisement
Articles by Tycel Jovelle Phillips, MD, University of Michigan
Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.
Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.
Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.
Advertisement
Latest Updated Articles
Novel Agents and Ongoing Trials in R/R Follicular LymphomaPublished: December 6th 2021 | Updated:
Emerging Agents for R/R MZLPublished: December 21st 2021 | Updated:
Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHLPublished: May 7th 2021 | Updated:
CHRONOS-1 and CHRONOS-3 Trials in R/R FL and Clinical ImplicationsPublished: November 29th 2021 | Updated:
Dr. Phillips on the Future of CAR T-Cell Therapy in MCLPublished: August 2nd 2021 | Updated:
- Role of Tazemetostat and Selecting Appropriate Therapies in R/R FL
Published: November 29th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5